This Article Full Text Full Text (PDF) All Versions of this Article: 111/18/2319    most recent 01.CIR.0000164237.58200.5Av1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freund, C. Articles by Bergmann, M. W. Search for Related Content PubMed PubMed Citation Articles by Freund, C. Articles by Bergmann, M. W. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections Biochemistry and metabolism Other heart failure ACE/Angiotension receptors Animal models of human disease Physiological and pathological control of gene expression

(Circulation. 2005;111:2319-2325.)
© 2005 American Heart Association, Inc.

Heart Failure

Requirement of Nuclear Factor-B in Angiotensin II– and Isoproterenol-Induced Cardiac Hypertrophy In Vivo

Christian Freund, MSc; Ruth Schmidt-Ullrich, PhD; Anthony Baurand, PhD; Sandra Dunger, MSc; Wolfgang Schneider, MD; Peter Loser, PhD; Amina El-Jamali, PhD; Rainer Dietz, MD, PhD; Claus Scheidereit, PhD; Martin W. Bergmann, MD

From the Franz-Volhard Clinic, Department of Cardiology, HELIOS Klinikum-Berlin, Charité Campus Berlin-Buch (C.F., S.D., W.S., R.D., M.W.B.); Robert Koch Institut (P.L.); and Max Delbrück Center for Molecular Medicine (R.S.-U., A.B., A.E.-J., C.S.), Berlin, Germany.

Correspondence to Martin W. Bergmann, MD, Franz Volhard Clinic, Charité Campus Buch, Wiltbergstr 50, 13125 Berlin, Germany (e-mail M.Bergmann{at}mdc-berlin.de), or to Dr Ruth Schmidt-Ullrich, PhD, Max-Delbrück-Center For Molecular Medicine, Robert-Rössle-Str 10, 13092 Berlin, Germany (e-mail rschmidt@mdc-berlin.de).

Received June 19, 2004; revision received November 24, 2004; accepted December 23, 2004.

Background— In vitro experiments have proposed a role of nuclear factor-B (NF-B), a transcription factor, in cardiomyocyte hypertrophy and protection against apoptosis. Currently, the net effect on cardiac remodeling in vivo under common stress stimuli is unclear.

Methods and Results— We have generated mice with cardiomyocyte-restricted expression of the NF-B super-repressor IBN (N^MHC) using the Cre/lox technique. N^MHC mice displayed an attenuated hypertrophic response compared with control mice on infusion of angiotensin II (Ang II) or isoproterenol by micro-osmotic pumps, as determined by echocardiography (left ventricular wall dimensions: control plus Ang II, x1.5±0.1 versus sham; N^MHC plus Ang II, x1.1±0.1 versus sham; P<0.05; n9), heart weight, and histological analysis. Real-time reverse-transcriptase polymerase chain reaction showed significantly reduced expression of hypertrophy markers ß-myosin heavy chain and atrial natriuretic peptide in Ang II–treated N^MHC mice (P<0.05 versus control plus Ang II; n=4). Neither cardiomyocyte apoptosis nor left ventricular dilatation was observed. In cultured adult rat cardiomyocytes, NF-B DNA binding activity was increased by both Ang II– and interleukin-6–related cytokines. The latter are known to be released by cardiac fibroblasts on Ang II stimulation and thus could locally increase the NF-B response of cardiomyocytes. Finally, results from in vitro and in vivo experiments suggest a role for NF-B in the regulation of prohypertrophic interleukin-6 receptor gp130 on mRNA levels.

Conclusions— These results indicate that targeted inhibition of NF-B in cardiomyocytes in vivo is sufficient to impair Ang II– and isoproterenol-induced hypertrophy without increasing the susceptibility to apoptosis.

Key Words: angiotensin • genes • hypertrophy • myocytes • nuclear factor-B

This article has been cited by other articles:

				B.-Y. Kang and J. L. Mehta Rosuvastatin Attenuates Ang II--Mediated Cardiomyocyte Hypertrophy via Inhibition of LOX-1 Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2009; 14(4): 283 - 291. [Abstract] [PDF]

				L. Zelarayan, A. Renger, C. Noack, M.-P. Zafiriou, C. Gehrke, R. van der Nagel, R. Dietz, L. de Windt, and M. W. Bergmann NF-{kappa}B activation is required for adaptive cardiac hypertrophy Cardiovasc Res, August 27, 2009; (2009) cvp237v2. [Abstract] [Full Text] [PDF]

				K. R. Brunt, M. R. Tsuji, J. H. Lai, R. T. Kinobe, W. Durante, W. C. Claycomb, C. A. Ward, and L. G. Melo Heme Oxygenase-1 Inhibits Pro-Oxidant Induced Hypertrophy in HL-1 Cardiomyocytes Experimental Biology and Medicine, May 1, 2009; 234(5): 582 - 594. [Abstract] [Full Text] [PDF]

				M. Endoh Novel signalling cascade for cardiac hypertrophy activation by uncoupling and internalization of {beta}1-adrenoceptors Cardiovasc Res, April 1, 2008; 78(1): 5 - 7. [Full Text] [PDF]

				E. Letavernier, J. Perez, A. Bellocq, L. Mesnard, A. de Castro Keller, J.-P. Haymann, and L. Baud Targeting the Calpain/Calpastatin System as a New Strategy to Prevent Cardiovascular Remodeling in Angiotensin II-Induced Hypertension Circ. Res., March 28, 2008; 102(6): 720 - 728. [Abstract] [Full Text] [PDF]

				X.-J. Zou, L. Yang, and S.-L. Yao Propofol Depresses Angiotensin II-Induced Cardiomyocyte Hypertrophy In Vitro Experimental Biology and Medicine, February 1, 2008; 233(2): 200 - 208. [Abstract] [Full Text] [PDF]

				N. Henke, R. Schmidt-Ullrich, R. Dechend, J.-K. Park, F. Qadri, M. Wellner, M. Obst, V. Gross, R. Dietz, F. C. Luft, et al. Vascular Endothelial Cell Specific NF-{kappa}B Suppression Attenuates Hypertension-Induced Renal Damage Circ. Res., August 3, 2007; 101(3): 268 - 276. [Abstract] [Full Text] [PDF]

				M. W. Bergmann and L. J. De Windt Linking Cardiac Mechanosensing at the Sarcomere M-Band, Nuclear Factor {kappa}B Signaling, and Cardiac Remodeling Hypertension, June 1, 2007; 49(6): 1225 - 1227. [Full Text] [PDF]

				A. Baurand, L. Zelarayan, R. Betney, C. Gehrke, S. Dunger, C. Noack, A. Busjahn, J. Huelsken, M. M. Taketo, W. Birchmeier, et al. {beta}-Catenin Downregulation Is Required for Adaptive Cardiac Remodeling Circ. Res., May 11, 2007; 100(9): 1353 - 1362. [Abstract] [Full Text] [PDF]

				P. Razeghi, M.-E. Wang, K. A. Youker, L. Golfman, S. Stepkowski, and H. Taegtmeyer Lack of NF-{kappa}B1 (p105/p50) attenuates unloading-induced downregulation of PPAR{alpha} and PPAR{alpha}-regulated gene expression in rodent heart Cardiovasc Res, April 1, 2007; 74(1): 133 - 139. [Abstract] [Full Text] [PDF]

				H. Lu, P. W. M. Fedak, X. Dai, C. Du, Y.-Q. Zhou, M. Henkelman, P. S. Mongroo, A. Lau, H. Yamabi, A. Hinek, et al. Integrin-Linked Kinase Expression Is Elevated in Human Cardiac Hypertrophy and Induces Hypertrophy in Transgenic Mice Circulation, November 21, 2006; 114(21): 2271 - 2279. [Abstract] [Full Text] [PDF]

				S. Frantz, K. Hu, B. Bayer, S. Gerondakis, J. Strotmann, A. Adamek, G. Ertl, and J. Bauersachs Absence of NF-{kappa}B subunit p50 improves heart failure after myocardial infarction FASEB J, September 1, 2006; 20(11): 1918 - 1920. [Abstract] [Full Text] [PDF]